Citations

Clear

141 citation(s) found for "Slack, S".

International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma
Ellin, Fredrik , Srour, Line, Slack, Graham W. , Smedby, Karin E. , Ansell, Stephen M. , Link, Brian K. , Relander, Thomas, Jerkeman, Mats, Connors, Joseph M. , Savage, Kerry J. , Link, Brian K , Maurer, Matthew J. , Jerkeman, Mats , Bennani, N. Nora , Cerhan, James R. , Feldman, Andrew L.

Mayo Clinic

Journal of Clinical Oncology | October 26, 2017 | Volume: 35 | Issue: 36 | Pages: 4019-4026

10.1200/jco.2017.73.8195 | PMID 29072976 Get It

Purpose Peripheral T-cell lymphomas (PTCLs) have aggressive clinical behavior. We have previously shown that event-free survival (EFS) at 24 months (EFS24) is a clinically useful end point in diffuse large B-cell lymphoma. Here, we assess EFS24 and subsequent overall survival (OS) in large, multinational PTCL cohorts. Patients and Methods Patients with systemic PTCL newly diagnosed from 2000 to 2012 and treated with curative intent were included from the United States and Sweden (initial cohorts) and from Canada (replication cohort). EFS was defined as time from date of diagnosis to progression after primary treatment, retreatment, or death. Subsequent OS was measured after achieving EFS24 or from the time of progression if it occurred within 24 months. OS rates were compared with the age-, sex-, and country-matched general population. Results Seven hundred seventy-five patients were included in the study (the median age at diagnosis was 64 years; 63% were men). Results were similar in the initial and replication cohorts, and a combined analysis was undertaken. Sixty-four percent of patients progressed within the first 24 months and had a median OS of only 4.9 months (5-year OS, 11%). In contrast, median OS after achieving EFS24 was not reached (5-year OS, 78%), although relapses within 5 years of achieving EFS24 occurred in 23% of patients. Superior outcomes after achieving EFS24 were observed in younger patients (≤ 60 years of age: 5-year OS, 91%). Conclusion EFS24 stratifies subsequent outcome in PTCL. Patients with PTCL with primary refractory disease or early relapse have extremely poor survival. However, more than one third of patients with PTCL remain in remission 2 years after diagnosis with encouraging subsequent OS, especially in younger patients. These marked differences in outcome suggest that EFS24 has utility for patient counseling, study design, and risk stratification in PTCL.
A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Czuczman, Myron S., Trněný, Marek , Davies, Andrew , Rule, Simon , Linton, Kim , Wagner‐Johnston, Nina D. , Gascoyne, Randy D. , Slack, Graham W. , Eberhard, David A., Hernandez‐Ilizaliturri, Francisco J. , Salles, Gilles , Zinzani, Pier Luigi , Wright, George W. , Staudt, Louis M. , Yang, Yandan , Lih, Chih-Jian, Russo, Jacqueline, Thakurta, Anjan , Hagner, Patrick R. , Fustier, Pierre , Song, Dale, Lewis, Ian D., Brousset, Pierre , Witzig, Thomas E. , Williams, P. Mickey , Lih, Chih‐Jian, Zinzani, Pier Luigi , Salles, Gilles A , Davies, Andrew , Trnĕný, Marek , Linton, Kim M , Wright, George

Mayo Clinic

Clinical Cancer Research | April 5, 2017 | Volume: 23 | Issue: 15 | Pages: 4127-4137

10.1158/1078-0432.ccr-16-2818 | PMID 28381416 Get It

Abstract Purpose: Randomized, multicenter, open-label, phase 2/3 trial investigating lenalidomide versus investigator's choice (IC) in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Experimental Design: Patients with DLBCL who received ≥2 prior therapies were stratified by DLBCL subtype [germinal center B-cell (GCB) vs. non-GCB; determined by immunohistochemistry (IHC)] and then randomized 1:1 to lenalidomide (25 mg/day, 21 days of 28-day cycle) or IC (gemcitabine, rituximab, etoposide, or oxaliplatin). Crossover to lenalidomide was permitted for IC-treated patients with radiologically confirmed progressive disease. The primary endpoint was overall response rate (ORR). Progression-free survival (PFS), overall survival, and subtype analysis [GCB vs. activated B-cell (ABC)] using gene expression profiling (GEP) were exploratory endpoints. Results: Stage 1: 102 DLBCL patients (by IHC: non-GCB, n = 54; GCB, n = 48) received ≥1 dose of lenalidomide or IC. Hematologic treatment-emergent adverse events with lenalidomide versus IC included neutropenia (42.6%; 36.4%), anemia (33.3%; 47.3%), thrombocytopenia (24.1%; 43.6%), and leukopenia (5.6%; 12.7%), respectively. Overall, lenalidomide-treated patients had an ORR of 27.5% versus 11.8% in IC (ORRs were similar regardless of IHC-defined DLBCL subtype). Median PFS was increased in patients receiving lenalidomide (13.6 weeks) versus IC (7.9 weeks; P = 0.041), with greater improvements in non-GCB patients (15.1 vs. 7.1 weeks, respectively; P = 0.021) compared with GCB (10.1 vs. 9.0 weeks, respectively; P = 0.550). Conclusions: The clinical benefit of lenalidomide monotherapy in DLBCL patients was more evident in the non-GCB subtype. Exploratory analyses suggest that this preferential benefit was more pronounced in the GEP-defined ABC population, demonstrating a need for additional studies of lenalidomide in DLBCL using GEP subtyping. Clin Cancer Res; 23(15); 4127–37. ©2017 AACR.
Understanding patient distress on day +100 of allogeneic stem cell transplant.
Padrnos, Leslie , Slack, James L., Khera, Nandita , Kosiorek, Heidi

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 34 | Issue: 3_suppl | Pages: 204-204

10.1200/jco.2016.34.3_suppl.204 Get It

204 Background: Allogeneic hematopoietic cell transplantation (HCT) is a medically complicated treatment modality used for various hematologic malignancies. Patterns and predictors of distress in post- transplant setting in a contemporary cohort of patients are not well-understood. Methods: 67 patients transplanted between 12/5/12- 4/21/15 completed National Comprehensive Cancer Network Distress Thermometer as part of their long term follow up clinic evaluation on day+100 after HCT. Demographic, socioeconomic and clinical outcome data were analyzed. A score ≥ 4 was considered distressed. Results: Mean age of patients was 50.8 years (range 20-72). Most patients were married or living with their significant other (83%), half were college graduates (58%), and half were employed full time (50%). 21 patients (31%) reported a distress score ≥ 4. Distressed patients reported increased problems with treatment decisions (15% vs 2%, p<0.05) and ability to have children (16% vs 0%, p<0.05). Physically, distressed patients were more likely to report fatigue (85% vs 44%, p <0.05), pain (60% vs 24%, p<0.05) and difficulty getting around (25% vs 7% p<0.05) Distressed patients were likely to report at least 1 emotional problem (N=16, 76%), and nearly a quarter reported ≥ 4 emotional problems (N=5, 24%). Specifically, sadness (25% vs 7%, p<0.05) and worry (64% vs 26%, p <0.01) were more common in distressed patients. Distressed patients had a longer length of hospitalization for transplant (30.8 days vs 24.9 p<0.001) and more hospitalized days during the first 100 days (34.9 vs 28.7 p<0.01). Conclusions: Approximately 30% of allogeneic HCT patients suffer significant distress at Day100 post-transplant. Distressed patients report problems with a variety of factors, including emotional, physical, family and practical issues that may impact function, compliance and quality of life. Higher number of hospitalized days is associated with increased distress and could be used to identify patients who may benefit from stress monitoring. Periodic screening of distress in HCT patients can help identify interventions to help improve patient reported outcomes.
Microbiologic yield of bronchoalveolar lavage specimens from stem cell transplant recipients
Sakata, Kenneth K. , Klassen, Christine L. , Bollin, Kathryn , Grys, Thomas E. , Slack, James L., Wesselius, Lewis , Vikram, Holenarasipur R. , Wesselius, Lewis J, Vikram, Holenarasipur R. , Grys, Thomas E

Mayo Clinic

Transplant Infectious Disease | February 21, 2017 | Volume: 19 | Issue: 3 | Pages: No page available

10.1111/tid.12684 | PMID 28218980 Get It

AbstractPurposeStem cell transplant (SCT) recipients commonly undergo bronchoalveolar lavage (BAL) collection as an infectious pulmonary work‐up. Previous studies report the utility and overall diagnostic yield of fiberoptic bronchoscopy with BAL in this vulnerable population, though none focused purely on microbiologic yield or made comparisons with less invasive means of pathogen detection. We sought to determine and elaborate on the microbiologic yield of BAL in SCT recipients, assess a correlation between BAL studies and less invasive means of pathogen detection, and assess the utility of repeating a BAL within 30 days.MethodsBetween January 1, 2009, and July 31, 2013, we reviewed medical records of 125 SCT recipients who underwent 179 BALs. In addition to demographic information and details pertaining to their SCT, a comprehensive review of their microbiologic data was performed and recorded.ResultsOur study showed an overall BAL microbiologic yield of 40%, despite 92% of patients receiving broad‐spectrum antimicrobial therapy at the time of the BAL procedure.ConclusionsAlthough an initial BAL sample in this population provides crucial microbiologic information, repeating the procedure within 30 days may have minimal additional microbiologic yield. BAL continues to be an essential diagnostic tool in SCT recipients undergoing an infectious pulmonary work‐up.
An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis
Lynch, Patrick M, Burke, Carol A. , Phillips, Robin, Morris, Jeffrey S. , Slack, Rebecca, Wang, Xuemei , Liu, Jun , Patterson, Sherri, Rodrı́guez-Bigas, Miguel A. , Half, Elizabeth , Bülow, Steffen, Latchford, Andrew , Clark, Sue, Ross, William A., Malone, Bonnie, Hasson, Hennie, Hawk, Ernest T. , Lynch, Patrick M, Sinicrope, Frank A. , Richmond, Ellen S. , Burke, Carol A

Mayo Clinic

Gut | March 20, 2015 | Volume: 65 | Issue: 2 | Pages: 286-295

10.1136/gutjnl-2014-307235 | PMID 25792707 Get It

Background and aim Although Non-steroidal anti-inflammatory drugs reduce colorectal adenoma burden in familial adenomatous polyposis (FAP), the utility of combining chemopreventive agents in FAP is not known. We conducted a randomised trial of celecoxib (CXB) versus CXB+diflouromethylornithine (DFMO) to determine the synergistic effect, if any. Methods The primary endpoint was % change in adenoma count in a defined field. Secondary endpoints were adenoma burden (weighted by adenoma diameter) and video review of entire colon/rectal segments. Adverse event (AEs) were monitored by National Cancer Institution toxicity criteria. Results 112 subjects were randomised: 60 men and 52 women at a mean age of 38 years. For the 89 patients who had landmark-matched polyp counts available at baseline and 6 months, the mean % change in adenoma count over the 6 months of trial was −13.0% for CXB+DFMO and −1.0% for CXB (p=0.69). Mean % change in adenoma burden was −40% (CXB+DFMO) vs −27% (CXB) (p=0.13). Video-based global polyp change was −0.80 for CXB+DFMO vs −0.33 for CXB (p=0.03). Fatigue was the only significant AE, worse on the CXB arm (p=0.02). Conclusions CXB combined with DFMO yielded moderate synergy according to a video-based global assessment. No significant difference in adenoma count, the primary endpoint, was seen between the two study arms. No evidence of DFMO-related ototoxicity was seen. There were no adverse cardiovascular outcomes in either trial arm and no significant increase in AEs in the CXB+DFMO arm of the trial. Differences in outcomes between primary and secondary endpoints may relate to sensitivity of the endpoint measures themselves. Trial registration number ClinicalTrials.gov number N01-CN95040.
Building Partnerships Through International Nursing Initiatives
Twedell, Diane M.

Mayo Clinic

The Journal of Continuing Education in Nursing | December 8, 2014 | Volume: 37 | Issue: 1 | Pages: 15-15

10.3928/00220124-20060101-05 Get It

What Every Nurse Needs to Know About Body Piercing
Mudderman, Nancy R., Mudderman, Mancy R

Mayo Clinic

The Journal of Continuing Education in Nursing | December 5, 2014 | Volume: 37 | Issue: 5 | Pages: 198-199

10.3928/00220124-20060901-05 | PMID 17004390 Get It

Dynamics of Leukemia Stem-like Cell Extinction in Acute Promyelocytic Leukemia
Werner, Benjamin , Gallagher, Robert E. , Paietta, Elisabeth , Litzow, Mark R. , Tallman, Martin S. , Wiernik, Peter H. , Slack, James L., Sun, Zhuoxin , Traulsen, Arne , Dingli, David , Willman, Cheryl L. , Dingli, David

Mayo Clinic

Cancer Research | August 1, 2014 | Volume: 74 | Issue: 19 | Pages: 5386-5396

10.1158/0008-5472.can-14-1210 | PMID 25082816 Get It

Abstract Many tumors are believed to be maintained by a small number of cancer stem–like cells, where cure is thought to require eradication of this cell population. In this study, we investigated the dynamics of acute promyelocytic leukemia (APL) before and during therapy with regard to disease initiation, progression, and therapeutic response. This investigation used a mathematical model of hematopoiesis and a dataset derived from the North American Intergroup Study INT0129. The known phenotypic constraints of APL could be explained by a combination of differentiation blockade of PML–RARα–positive cells and suppression of normal hematopoiesis. All-trans retinoic acid (ATRA) neutralizes the differentiation block and decreases the proliferation rate of leukemic stem cells in vivo. Prolonged ATRA treatment after chemotherapy can cure patients with APL by eliminating the stem-like cell population over the course of approximately one year. To our knowledge, this study offers the first estimate of the average duration of therapy that is required to eliminate stem-like cancer cells from a human tumor, with the potential for the refinement of treatment strategies to better manage human malignancy. Cancer Res; 74(19); 5386–96. ©2014 AACR.
Transgene-Free Disease-Specific Induced Pluripotent Stem Cells from Patients with Type 1 and Type 2 Diabetes
Kudva, Yogish C. , Ohmine, Seiga, Greder, Lucas, Dutton, James R. , Armstrong, Adam, Lamo, Josep Genebriera De, Khan, Yulia, Thatava, Tayaramma, Hasegawa, Mamoru, Fusaki, Noemi, Slack, Jonathan M.W. , Ikeda, Yasuhiro

Mayo Clinic

Stem Cells Translational Medicine | May 31, 2012 | Volume: 1 | Issue: 6 | Pages: 451-461

10.5966/sctm.2011-0044 | PMID 23197849 Get It

Abstract The induced pluripotent stem cell (iPSC) technology enables derivation of patient-specific pluripotent stem cells from adult somatic cells without using an embryonic cell source. Redifferentiation of iPSCs from diabetic patients into pancreatic islets will allow patient-specific disease modeling and autologous cell replacement therapy for failing islets. To date, diabetes-specific iPSCs have been generated from patients with type 1 diabetes using integrating retroviral vectors. However, vector integration into the host genome could compromise the biosafety and differentiation propensities of derived iPSCs. Although various integration-free reprogramming systems have been described, their utility to reprogram somatic cells from patients remains largely undetermined. Here, we used nonintegrating Sendai viral vectors to reprogram cells from patients with type 1 and type 2 diabetes (T2D). Sendai vector infection led to reproducible generation of genomic modification-free iPSCs (SV-iPSCs) from patients with diabetes, including an 85-year-old individual with T2D. SV-iPSCs lost the Sendai viral genome and antigens within 8–12 passages while maintaining pluripotency. Genome-wide transcriptome analysis of SV-iPSCs revealed induction of endogenous pluripotency genes and downregulation of genes involved in the oxidative stress response and the INK4/ARF pathways, including p16INK4a, p15INK4b, and p21CIP1. SV-iPSCs and iPSCs made with integrating lentiviral vectors demonstrated remarkable similarities in global gene expression profiles. Thus, the Sendai vector system facilitates reliable reprogramming of patient cells into transgene-free iPSCs, providing a pluripotent platform for personalized diagnostic and therapeutic approaches for diabetes and diabetes-associated complications.
RNAi screening of the kinome with cytarabine in leukemias
Tibes, Raoul , Bogenberger, James M. , Chaudhuri, Leena, Hagelstrom, R. Tanner, Chow, Donald, Buechel, Megan, Gonzales, Irma M. , Demuth, Tim, Slack, James L., Braggio, Esteban , Yin, Hongwei , Arora, Shilpi , Azorsa, David O. , Mesa, Ruben A. , Braggio, Esteban , Bogenberger, James

Mayo Clinic

Blood | January 21, 2012 | Volume: 119 | Issue: 12 | Pages: 2863-2872

10.1182/blood-2011-07-367557 | PMID 22267604 Get It

AbstractTo identify rational therapeutic combinations with cytarabine (Ara-C), we developed a high-throughput, small-interference RNA (siRNA) platform for myeloid leukemia cells. Of 572 kinases individually silenced in combination with Ara-C, silencing of 10 (1.7%) and 8 (1.4%) kinases strongly increased Ara-C activity in TF-1 and THP-1 cells, respectively. The strongest molecular concepts emerged around kinases involved in cell-cycle checkpoints and DNA-damage repair. In confirmatory siRNA assays, inhibition of WEE1 resulted in more potent and universal sensitization across myeloid cell lines than siRNA inhibition of PKMYT1, CHEK1, or ATR. Treatment of 8 acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myeloid leukemia (CML) cell lines with commercial and the first-in-class clinical WEE1 kinase inhibitor MK1775 confirmed sensitization to Ara-C up to 97-fold. Ex vivo, adding MK1775 substantially reduced viability in 13 of 14 AML, CML, and myelodysplastic syndrome patient samples compared with Ara-C alone. Maximum sensitization occurred at lower to moderate concentrations of both drugs. Induction of apoptosis was increased using a combination of Ara-C and MK1775 compared with using either drug alone. WEE1 is expressed in primary AML, ALL, and CML specimens. Data from this first siRNA-kinome sensitizer screen suggests that inhibiting WEE1 in combination with Ara-C is a rational combination for the treatment of myeloid and lymphoid leukemias.